What We're Reading: Page 243
Industry reads hand-picked by our editors
May 07, 2019
-
The New Yorker
The Birth-Tissue Profiteers
-
The Wall Street Journal
Making monkeys out of the Sohn investing gurus
-
Axios
How to save $80 billion a year on prescription drugs
-
Kaiser Health News
Meth vs. opioids: America has two drug epidemics, but focuses on one
May 06, 2019
-
C&EN
Stanley Crooke on finally making sense out of antisense
-
STAT
Scientists see hope in rare disease drug Wall Street has doubted
-
The Wall Street Journal
Want David Solomon's Take on Something? Buy a Goldman Share and Show Up
-
The New York Times
80,000 Deaths. 2 Million Injuries. It’s Time for a Reckoning on Medical Devices.
May 03, 2019
-
MIT Technology Review
The search for the kryptonite that can stop CRISPR
-
New England Journal of Medicine
Pharmaceutical Protections in U.S. Trade Deals — What Do Americans Get in Return?
-
South China Morning Post
As biotechnology firms become the darlings of Hong Kong's IPO market, their executives get outsized pay packets. Here’s why
May 02, 2019
-
The Economist
Antibiotics biotech firms are struggling
-
BioCentury
China makes headway on trade secret reform
-
Boston Business Journal
Charles River Labs says its biotech, pharma clients' data was hacked
-
Bloomberg
Crispr babies vs. 'bubble boy': only one was about the patient
May 01, 2019
Apr 30, 2019
-
The Washington Post
Why Vermont's single-payer effort failed and what Democrats can learn from it
-
In the Pipeline
The Going Rates, 2019 Edition
-
CNN
Our antibiotics are no match for superbugs, and it's a 'global crisis,' UN report says
-
Reuters
Novartis's Sandoz strikes deal for biosimilar of Herceptin
Apr 29, 2019
-
The Wall Street Journal
Cancer-drug giant Roche loses edge as rivals grow
-
Kaiser Health News
Is insulin's high cost keeping diabetes patients from taking their medicine?
-
Bloomberg
Snoop Dogg-backed medical weed firm seeks big pharma funding
-
Reuters
The obscure advisory committees at the heart of the U.S. drug pricing debate
Previous
